Linzolid PFS-100 ml

Patients who Commence Treatment on the Parenteral Formulation may be Switched to Oral Presentation when Clinically Indicated. In such Circumstances, no Dose Adjustment is Required as Linezolid has an Oral Bioavailability of Approximately 100%. The Injection should be Administered Over a Period of 30 to 120 Minutes. The Film-Coated Tablets or Oral Suspension may be Taken with or without Food.
Complicated Skin and Skin Structure Infections, Community-Acquired Pneumonia, Including Concurrent Bacteremia-Pediatric Patients (Birth Through 11 Years of Age): 10 mg/kg IV or Oral t.i.d.
Adults and Adolescents (12 Years and Older): 600 mg IV or Oral b.i.d.
Recommended Duration of Treatment (Consecutive Days): 10 to 14.
Nosocomial Pneumonia, Vancomycin-Resistant Enterococcus Faecium Infections Including Concurrent Bacteremia-Pediatric Patients (Birth through 11 Years of Age): 10 mg/kg IV or Oral t.i.d.
Adults and Adolescents (12 Years and Older): 600 mg IV or oral b.i.d.
Recommended Duration of Treatment (Consecutive Days): 14 to 28.
Uncomplicated Skin and Skin Structure Infections-Pediatric Patients (Birth Through 11 Years of Age): <5 Years: 10 mg/kg oral t.i.d. 5-11 Years: 10 mg/kg Oral b.i.d Adults and Adolescents (12 Years and Older): Adults: 400 mg oral b.i.d. Adolescents: 600 mg Oral b.i.d Recommended Duration of Treatment (Consecutive Days): 10 to 14. Neonates <7 Days: Most Pre-Term Neonates <7 Days of Age (Gestational Age <34 Weeks) have Lower Systemic Linezolid Clearance Values and Larger AUC Values than many Full-Term Neonates and Older Infants. These Neonates should be Initiated with a Dosing Regimen of 10 mg/kg Every 12 hours. Consideration may be Given to the Use of 10 mg/kg in Every Eight Hours Regimen in Neonates with a Sub-Optimal Clinical Response. All Neonatal Patients should Receive 10 mg/kg t.i.d. by 7 Days of Life.